UK Researchers Developing Duplex qPCR Assay to Monitor BCR-ABL1-Linked Blood Cancers

The group from Imperial College London's Hammersmith Hospital has developed a duplex qPCR assay that measures both BCR-ABL1 target and endogenous control transcripts in the same reaction with no loss of sensitivity compared to a previously used simplex test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.